Southpoint Capital Advisors LP Fennec Pharmaceuticals Inc. Transaction History
Southpoint Capital Advisors LP
- $4.43 Billion
- Q1 2024
A detailed history of Southpoint Capital Advisors LP transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Southpoint Capital Advisors LP holds 4,077,214 shares of FENC stock, worth $24.9 Million. This represents 1.02% of its overall portfolio holdings.
Number of Shares
4,077,214
Previous 4,077,214
-0.0%
Holding current value
$24.9 Million
Previous $45.7 Million
0.89%
% of portfolio
1.02%
Previous 1.0%
Shares
2 transactions
Others Institutions Holding FENC
# of Institutions
69Shares Held
14.4MCall Options Held
53.2KPut Options Held
83.9K-
Sonic Gp LLC Honolulu, HI2.41MShares$14.7 Million35.34% of portfolio
-
Dg Capital Management, LLC New York, NY1.51MShares$9.24 Million10.39% of portfolio
-
Solas Capital Management, LLC Darien, CT1.11MShares$6.78 Million8.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.01MShares$6.19 Million0.0% of portfolio
-
Black Rock Inc. New York, NY927KShares$5.67 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $159M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...